Comparing Medications for DSM-5 PTSD in Routine VA Practice.

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Research

Background:

• Several medications, including fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine, have demonstrated efficacy in treating posttraumatic stress disorder (PTSD).
• Previous research comparing these agents in Veterans Affairs (VA) medical records found no significant differences in symptom reduction.
• The current study aimed to address limitations of prior research, such as inconsistent treatment durations and lack of functional outcome assessment.

Purpose of the Study:

• To compare the efficacy of fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine in achieving symptom remission for posttraumatic stress disorder (PTSD).
• To evaluate the impact of medication continuation versus cessation on the need for acute psychiatric services.

Main Methods:

• A cohort of 834 VA outpatients with DSM-5 PTSD diagnoses were analyzed.
• Patients initiated one of the five specified medications and met criteria for treatment duration and dose.
• Changes in PTSD Checklist (PCL-5) scores and remission rates were assessed over a 12-week acute phase, with psychiatric service use tracked for 6 months post-treatment.

Main Results:

• Patients taking venlafaxine showed significantly higher rates of PTSD symptom remission compared to fluoxetine, paroxetine, sertraline, and topiramate.
• No differences in acute psychiatric service use were observed between medication groups during the continuation phase.
• Patients who continued their prescribed medication were less likely to require acute psychiatric services (Hazard Ratio = 0.55, P = 0.03).

Conclusions:

• Venlafaxine may offer an advantage in achieving acute-phase remission for PTSD in routine clinical practice, warranting further investigation.
• Discontinuing PTSD medication during the continuation phase is associated with an increased risk of requiring acute psychiatric care.
• The choice of medication may influence remission rates, but continued treatment is crucial for maintaining stability and reducing healthcare utilization.